Pages that link to "Q33401272"
Jump to navigation
Jump to search
The following pages link to Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial (Q33401272):
Displaying 50 items.
- Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge (Q26781273) (← links)
- Children's Oncology Group's 2013 blueprint for research: renal tumors (Q27000449) (← links)
- Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model (Q27302940) (← links)
- Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. (Q33168449) (← links)
- A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. (Q33629947) (← links)
- The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment (Q33769429) (← links)
- Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches (Q34194075) (← links)
- Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets (Q34504946) (← links)
- Cediranib for metastatic alveolar soft part sarcoma (Q34651131) (← links)
- Biology and management of clear cell sarcoma: state of the art and future perspectives (Q34677457) (← links)
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors (Q34964958) (← links)
- Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells (Q35214544) (← links)
- Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies (Q35315403) (← links)
- Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines (Q35862728) (← links)
- Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers (Q36001179) (← links)
- Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article (Q36151526) (← links)
- Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma (Q36214648) (← links)
- Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. (Q36389964) (← links)
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma (Q36551653) (← links)
- Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib (Q36925182) (← links)
- Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. (Q37137050) (← links)
- Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma. (Q37293444) (← links)
- Recent developments in the treatment of renal cell carcinoma (Q37300942) (← links)
- Inflammatory stress and sarcomagenesis: a vicious interplay (Q37378867) (← links)
- Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines (Q37427337) (← links)
- Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists. (Q37589535) (← links)
- Surgical management and outcome of spinal alveolar soft part sarcoma (ASPA): a case series of five patients and literature review (Q37628105) (← links)
- Targeting angiogenesis in renal cell carcinoma (Q38132231) (← links)
- Targeted therapies for sarcomas: new roles for the pathologist (Q38151788) (← links)
- Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies (Q38197031) (← links)
- The role of inflammation in sarcoma (Q38211082) (← links)
- Soft tissue sarcomas, a look into the future: different treatments for different subtypes (Q38232373) (← links)
- Role of genetic and molecular profiling in sarcomas (Q38458016) (← links)
- Clear cell sarcoma-like tumor of the gastrointestinal tract, presenting as a second malignancy after childhood hepatoblastoma (Q38565428) (← links)
- Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. (Q38591828) (← links)
- Phosphoproteomics in translational research: a sarcoma perspective. (Q38708614) (← links)
- Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future (Q38724079) (← links)
- The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma (Q38806970) (← links)
- Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats (Q38986669) (← links)
- Cabozantinib as a novel therapy for renal cell carcinoma (Q39490838) (← links)
- Advanced alveolar soft part sarcoma responds to apatinib (Q41473058) (← links)
- We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas (Q42333740) (← links)
- Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma (Q42363585) (← links)
- Lingual alveolar soft part sarcoma responsive to pazopanib: A case report (Q47132516) (← links)
- Malignant Gastrointestinal Neuroectodermal Tumor: a Unique Rare Neoplasm (Q47569420) (← links)
- Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (Q49820833) (← links)
- A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors (Q49881127) (← links)
- Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. (Q50985091) (← links)
- A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). (Q51031755) (← links)
- A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. (Q53032609) (← links)